The U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for several inflammatory diseases
The U.S. Department of Health and Human Services released a proposed rule for public comment that would establish disincentives for healthcare providers found by the HHS Office...
The agency is concerned as these products can be dangerous for preterm infants and are being illegally sold to treat or prevent diseases in preterm infants in hospital settings...